Table 1.
Baseline characteristics of the retransitioning cohort and the biosimilar remainder cohort.
| Baseline characteristics | Retransitioning cohort | Biosimilar remainder cohort |
|---|---|---|
| n = 44 | n = 127 | |
| Median (IQR) age at transitioning (years) | 39.9 (28.4–52.8) | 44.0 (31.8–57.7) |
| Females (%) | 29 (65.9%) | 62 (48.9%) |
| Hospital | ||
| Medisch Spectrum Twente | 29 (65.9%) | 84 (66.2%) |
| Spaarne Gasthuis | 15 (34.1%) | 43 (33.8%) |
| Disease | ||
| Crohn’s disease | 25 (56.8%) | 75 (59.0%) |
| Ulcerative colitis | 12 (27.2%) | 34 (26.8%) |
| Unknown | 7 (16.0%) | 18 (14.2%) |
| Median (IQR) duration of infliximab originator prior to transitioning (years) | 4.6 (2.3–4.9) | 3.7 (2.5–4.8) |
| Median (IQR) dose at index date (mg) | 400 (300–500) | 400 (350–500) |
| Median (IQR) dosing interval at index date (days) | 48.5 (42–56) | 56 (45–56) |
| Biologicals prior to transitioning | ||
| Only infliximab | 34 (77.3%) | 114 (89.8%) |
| Adalimumab | 8 (18.1%) | 8 (6.3%) |
| Ustekinumab | 1 (2.3%) | 4 (3.1%) |
| Adalimumab and golimumab | 0 | 1 (0.8%) |
| Adalimumab and ustekinumab | 1 (2.3%) | 0 |
| Median (IQR) follow-up (years) | 2.8 (2.4–3.2) | 2.9 (2.4–3.2) |
IQR, interquartile range.